跳至主要内容
临床试验/NL-OMON48100
NL-OMON48100已完成2 期

Effects of nicotinamide riboside (vitamin B3) in patients with Ataxia Telangiectasia - Vitamine B3 in A-T

Radboud Universitair Medisch Centrum0 个研究点目标入组 25 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 99(—)

入选标准

  • -A-T patients who visit our outpatient clinic
  • -Genetically confirmed diagnosis of A-T by the identification of pathogenic mutations of the ATM gene.
  • -Age * 2 years or older and bodyweight * 12 Kg
  • -Informed consent

排除标准

  • -Additional medical condition or illness that impair the patient*s ability to participate in the study (e.g. actual treatment of a malignancy, active infection, poorly controlled diabetes mellitus, hypertension, organ failure, clinically significant hematological or biochemical abnormalities different from the usual abnormalities in A-T)
  • -Elevated serum transaminases (> 2 times upper limit of normal)
  • -Participation in another interventional study at start of the study or during the study
  • -pregnancy/ breastfeeding

研究者

相似试验

Effects of nicotinamide riboside (vitamin B3) in... | 临床试验